Q-omics provides the consensus-scored MIR4690 profile across patient tissues and cancer cell-line models. MIR4690 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR4690 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, MIR4690 RNA expression shows 5,573 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight THCA, COAD, and KIRC as cancer lineages where MIR4690 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4690 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4690 survival associations across molecular data types. MIR4690 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4690 RNA expression–survival associations across cancer types. High MIR4690 expression shows unfavorable associations in THCA, KIRC, READ, UCS and OV, but favorable associations in KIRP. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR4690 RNA expression.
This table summarizes MIR4690 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4690. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4690 shows higher tumor expression in COAD and THCA. The COAD box plot shows higher MIR4690 RNA expression in tumor versus normal tissue (log2 FC = +0.364, t-test p = .024).
This table shows molecular features associated with MIR4690 in patient tissues and cancer cell lines. In patient samples, MIR4690 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
